

**DESCRIPTION**

**Source** Chinese Hamster Ovary cell line, CHO-derived  
Thr36-Asn233, with a C-terminal 6-His tag  
Accession # Q14002

**N-terminal Sequence Analysis** Thr36

**Predicted Molecular Mass** 23 kDa

**SPECIFICATIONS**

**SDS-PAGE** 42-52 kDa, reducing conditions

**Activity** Measured by its binding ability in a functional ELISA.  
When Recombinant Human CEACAM-7 is immobilized at 0.1 µg/mL (100 µL/well), the concentration of Recombinant Human CEACAM-1/CD66a (Catalog # 2244-CM) that produces 50% of the optimal binding response is approximately 1.6-8 ng/mL.

**Endotoxin Level** <0.10 EU per 1 µg of the protein by the LAL method.

**Purity** >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

**Formulation** Lyophilized from a 0.2 µm filtered solution in PBS See Certificate of Analysis for details.

**PREPARATION AND STORAGE**

**Reconstitution** Reconstitute at 500 µg/mL in PBS.

**Shipping** The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

**Stability & Storage** Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

- 12 months from date of receipt, -20 to -70 °C as supplied.
- 1 month, 2 to 8 °C under sterile conditions after reconstitution.
- 3 months, -20 to -70 °C under sterile conditions after reconstitution.

**BACKGROUND**

Carcinoembryonic antigen-related cell adhesion molecule 7 (CEACAM-7), also known as CGM2, is an approximately 40 kDa GPI-anchored glycoprotein in the CEACAM family of adhesion molecules (1). Mature human CEACAM-7 consists of two Ig-like domains followed by the GPI anchor (2). Alternative splicing generates a short isoform that lacks the second Ig-like domain. CEACAM-7 is preferentially expressed on the luminal surface of epithelial cells near the mouth of colonic crypts and on pancreatic ductal epithelial cells (3, 4). It is down-regulated during colorectal adenoma progression (2-6) but can be up-regulated during the development of gastric carcinoma (7). R&D Systems in-house testing indicates that CEACAM-7 binds to CEACAM-1, consistent with the heterophilic interaction of CEACAM-1 with other CEACAM family members (1, 8, 9).

**References:**

1. Tchoupa, A.K. *et al.* (2014) Cell Commun. Signal. **12**:27.
2. Thompson, J. *et al.* (1994) J. Biol. Chem. **269**:32924.
3. Thompson, J. *et al.* (1997) Cancer Res. **57**:1776.
4. Scholzel, S. *et al.* (2000) Am. J. Pathol. **156**:595.
5. Nollau, P. *et al.* (1997) Cancer Res. **57**:2354.
6. Nollau, P. *et al.* (1997) Am. J. Pathol. **151**:521.
7. Zhou, J. *et al.* (2011) World J. Surgical Oncol. **9**:172.
8. Markel, G. *et al.* (2004) J. Immunol. **173**:3732.
9. Oikawa, S. *et al.* (1992) Biochem. Biophys. Res. Commun. **186**:881.